Search clinical trials for: Epidermal growth factor receptor

Total 57883 results

Checkpoint Therapeutics, Inc.

Completed

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Lung Diseases | Adenocarcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States, Thailand, New Zealand, Australia, Poland
Hoffmann-La Roche

Terminated

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy (Veronica)

Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

Canada, United States, United Kingdom, Australia, Germany
Corporal Michael J. Crescenz VA Medical Center
University of Pennsylvania; National Institute on Aging (NIA)

Completed

Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

Heart Failure | Congestive Heart Failure

United States
Spanish Lung Cancer Group

Completed

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR (EURTAC)

Non-Small Cell Lung Cancer

Spain, France, Italy
Spanish Lung Cancer Group

Completed

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma (SLAT)

Non-small Cell Lung Cancer

Spain
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer

Italy, Belgium, Canada, United Kingdom, Argentina, Australia, Austria, Brazil, Bulgaria, China, Croatia, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, Indonesia, Irelan... and more
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

United States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (reSURFACE 1)

Plaque Psoriasis
Daiichi Sankyo Co., Ltd.
AstraZeneca

Completed

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Neoplasm, Gastrointestinal

Korea, Republic of, Japan
MedSIR
Roche Pharma AG; Experior

Completed

T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (THELMA)

Breast Cancer

France, Spain
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Novartis Pharmaceuticals

Completed

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Germany, France, Spain, Israel
Genentech, Inc.

Completed

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

Breast Cancer

United States, Korea, Republic of
Daiichi Sankyo, Inc.

Terminated

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Eli Lilly and Company
University of Colorado, Denver; Quintiles, Inc.; PPD; Parexel; Laboratory Corporation... and other collaborators

Completed

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin (INSPIRE)

Non Small Cell Lung Cancer

Belgium, Brazil, Russian Federation, United Kingdom, Australia, Germany, Hungary, Italy, Romania, United States, Austria, Canada, Croatia, France, Greece, Poland, Portugal, Slovakia, South Africa, Spain
Chul Kim
Bristol-Myers Squibb; AstraZeneca; Walter Reed National Military Medical Center; Hackensack Meridian Health

Active, not recruiting

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Nonsmall Cell Lung Cancer | EGFR Gene Mutation

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (PUFFIN)

Breast Cancer

China
Genentech, Inc.

Completed

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Metastatic Breast Cancer

United States
Pfizer

Terminated

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Early Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Neoplasms, Breast

United States
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Completed

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Colorectal Neoplasm

United States, Spain, Japan, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Advanced Metastatic Breast Cancer

Germany
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Cancer | Non Small Cell Lung Cancer

United Kingdom
NSABP Foundation Inc
Washington University School of Medicine; Breast Cancer Research Foundation

Active, not recruiting

NSABP Biospecimen Discovery Project

Breast Cancer

United States
Daiichi Sankyo, Inc.
Daiichi Sankyo UK Ltd.

Terminated

A Study of DS-2248 in Participants With Advanced Solid Tumors

Non-small Cell Lung Carcinoma | Solid Tumors

United States
Renske Altena

Terminated

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer (PREDIXIIHER2)

HER2-positive Breast Cancer | Early-stage Breast Cancer

Sweden
Novartis Pharmaceuticals
Breast International Group; SOLTI Breast Cancer Research Group

Completed

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (Neo ALTTO)

Neoplasms, Breast

France, Spain, United Kingdom, Belgium, Argentina, Czechia, Germany, Italy, Norway, Russian Federation, Sweden, Taiwan, Hong Kong, Brazil, Hungary, India, Korea, Republic of, Pakistan, Peru, Romania, South Africa, Ukraine, Canada, Lit...
Hoffmann-La Roche

Completed

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (BERENICE)

Breast Cancer

United States, Canada, Denmark, France, Italy, Poland, Portugal, Spain, United Kingdom, Norway, Germany, Mexico
OmicsWay Corp.
Oncobox Ltd., Russia; Vitamed LLC, Russia; Republican Oncological Dispensary...

Active, not recruiting

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

HER2-positive Breast Cancer

United States, Russian Federation
Dartmouth-Hitchcock Medical Center
Dartmouth College

Completed

A Microdose Evaluation Study of ABY-029 in Primary Sarcoma

Primary Soft-tissue Sarcoma

United States
Ariad Pharmaceuticals

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

Carcinoma, Non-Small-Cell Lung | Lymphoma, Large-Cell, Anaplastic
Daiichi Sankyo, Inc.
Bristol-Myers Squibb; AstraZeneca

Active, not recruiting

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Breast Cancer | Urothelial Carcinoma

United States, Spain, Italy, Belgium, France, Germany, United Kingdom
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

Type 2 Diabetes

China
Dartmouth-Hitchcock Medical Center
Dartmouth College

Completed

A Microdose Evaluation Study of ABY-029 in Recurrent Glioma (ABY-029)

Glioma

United States
Korea University Guro Hospital
Chong Kun Dang Pharmaceutical Corp.

Active, not recruiting

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Centre Leon Berard

Completed

Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR) (CICAFIX)

Colorectal Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Epidermal Growth Factor Receptor Inhibitor

France
Pfizer

Terminated

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Australia, Japan
AstraZeneca
iOMEDICO AG, Freiburg, Germany

Completed

PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC (PANORAMA)

Carcinoma, Non-Small-Cell Lung

Germany
Sun Yat-sen University

Completed

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment (EGFR-TKIs)

Non-small Cell Lung Cancer

China
AbbVie

Completed

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Advanced Solid Tumors Cancer

United States, Australia, Israel
ISU Abxis Co., Ltd.

Active, not recruiting

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Solid Tumor

Korea, Republic of
Hoffmann-La Roche

Completed

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)

Breast Neoplasms

Hungary, Italy, United Kingdom, Canada, Czechia, Bulgaria, Croatia, Dominican Republic, France, Germany, Greece, Guatemala, Hong Kong, Indonesia, Ireland, Korea, Republic of, Netherlands, Panama, Peru, Poland, Portugal, Slovakia, Spain and more
AbbVie

Terminated

UNITE Study: Understanding New Interventions With GBM ThErapy

Glioblastoma Multiforme

United States, Australia, Germany, Netherlands, United Kingdom
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

India
The Affiliated Hospital of Qingdao University

Completed

Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection

Healthy Volunteers

China
European Organisation for Research and Treatment...

Active, not recruiting

Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study (GEM)

EGFR Mutation Positive Non Small Cell Lung Cancer

United Kingdom
National Cancer Institute, Egypt

Completed

The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

Prostate Cancer Metastatic

Egypt
Novartis Pharmaceuticals

Completed

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (BOLERO-6)

Breast Cancer

Belgium, Hungary, Spain, Argentina, Russian Federation, Sweden, Lebanon, Australia, Denmark, Ireland, United Kingdom, Thailand, Turkey, Peru, Brazil, Malaysia, India, United States
Novartis Pharmaceuticals

Completed

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Breast Neoplasms

United States, France, Spain, United Kingdom, Croatia, Turkey, Netherlands, Argentina, Australia, Canada, Czechia, Germany, Italy, Poland, Russian Federation, Brazil, Bulgaria, Chile, Denmark, Hungary, Ireland, Peru, South Africa, Col... and more

Search clinical trials for: Epidermal growth factor receptor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations